This Month in JNM

April 1, 2018

Hot Topics – Imaging cardiac repair and regeneration: Thackeray and Bengel look at the evolution of regenerative heart medicine and call for imaging adaptation to provide tools to evaluate molecular mechanisms underlying endogenous healing. Page 549

The State of the Art – PET/CT in local ablative therapies: Aarntzen and colleagues systematically review current literature on the use of 18F-FDG PET/CT to monitor the efficacy of local ablative therapies, identify patterns across studies, and offer recommendations for the future. Page 551

Continuing Education – PET/CT for prostate RT planning: Calais and colleagues provide an educational overview of the literature on the effect of PET/CT on prostate radiotherapy planning, the potential of various PET/CT strategies and tracers on planning, and current relevant investigations. Page 557

Focus on Molecular Imaging – 18F radiochemistry: Bernard-Gauthier and colleagues focus on recent 18F-labeling methodologies for B-18F, Si-18F, Al-18F, and iodine (III)-mediated radiofluorination via spirocyclic iodonium ylide technology. Page 568 

Editorial – Challenges in nuclear endocrinology: Taïeb and colleagues offer perspective on the future of nuclear endocrinology in prognostication and tumor grading, therapeutic drug monitoring, and immunology applications. Page 573

PET/CT and HNSCC: Rohde and colleagues determine whether staging of head and neck squamous cell carcinoma by upfront 18F-FDG PET/CT predicts survival better than traditional imaging strategies based on chest x-ray or CT plus MR imaging. Page 575

166Ho radioembolization: Prince and colleagues investigate the efficacy of and response to 166Ho microsphere radioembolization in patients with liver metastases refractory to systemic therapy and ineligible for surgical resection. Page 582

Interim PET and PTCL: Cottereau and colleagues ask whether therapeutic response in peripheral T-cell lymphoma as assessed with PET/CT plus baseline total metabolic tumor volume can identify early relapse or refractory disease. Page 589

BSI in 223Ra therapy: Fosbøl and colleagues detail the prognostic value of the scintigraphy-derived bone scan index in patients with advanced metastatic castration-resistant prostate cancer under treatment with 223RaCl2.  Page 596

Tumor volume in 18F-FET PET and 3D MRSI: Mauler and colleagues compare the results of 18F-FET PET imaging of amino acid transport and proton MR spectroscopy imaging of cell turnover ratios in defining tumor extent of cerebral gliomas.  Page 603

Invited Perspective – Targeting pontine glioma: Oyen and Jones report on the value of molecular imaging of target expression as a tool for in vivo immunohistochemistry and preview a related study in this issue of JNM. Page 610

Drug-uptake and tumor morphology in DIPG: Veldhuijzen van Zanten and colleagues combine data from a 89Zr-bevacizumab study and autopsy to analyze multiregional in vivo and ex vivo uptake, tumor histology, and vascular morphology in end-stage diffuse intrinsic pontine glioma. Page 612

177Lu SPECT/CT kidney imaging: Tran-Gia and Lassmann describe an optimal setup for activity determination of 177Lu-based SPECT/CT renal imaging using 3D-printed phantoms and 2 commercially available methods. Page 616 

68Ga-THP-PSMA PET/CT in prostate cancer: Hofman and colleagues monitor the safety and efficacy of a 68Ga-prostate-specific membrane antigen agent that features single-step kit-based radiolabeling for PET/CT imaging in prostate cancer before prostatectomy. Page 625

PSMA-1007 in prostate cancer recurrence: Giesel and colleagues assess the potential of 18F-prostate-specific membrane antigen-1007 PET for disease localization in patients with biochemical recurrence of prostate cancer after local treatment. Page 632

Dose calibrators and 68Ga: Bailey and colleagues report on a systematic miscalibration during site validation of a multicenter clinical PET trial using 68Ga, manifested as a consistent underestimation in quantitative accuracy in a range of PET systems. Page 636

Dual-labeled PSMA-11: Baranski and colleagues describe development of dual-labeled prostate-specific membrane antigen inhibitors derived from 68Ga-PSMA-11 to allow accurate intraoperative detection of prostate-specific membrane antigen–positive tumors. Page 639

Cold-antibody boost after a-particle therapy: Palm and colleagues report on simulations of penetration of radiolabeled monoclonal antibodies into microtumors with radii of up to 400 mm and calculate optimization of an added boost for different tumor sizes. Page 646

123I-mIBG planar and SPECT HMRs: Alvi and colleagues report on a semiautomated methodology for assessing heart-to-mediastinum ratio with a dedicated cardiac multipinhole SPECT/CT system and correlate SPECT-derived lower normal limits with those from planar derived ratios. Page 652

11C-MeNER PET and noradrenaline in PD: Nahimi and colleagues use PET and a highly selective radiolabeled inhibitor of noradrenaline transporters to map transporter density in groups of patients with Parkinson disease and controls. Page 659

FEATURED CLINICAL INVESTIGATION ARTICLEPretreatment 5-HTT binding and remission: Ananth and colleagues investigate whether 5-HTT and 5-HT1A binding as assessed on PET imaging can improve prediction of posttreatment remission status in patients with major depressive disorder. Page 665

18F-THK5351 PET and pathology correlation: Harada and colleagues examine spatial patterns of tracer binding, amyloid-b, tau, and gliosis in an individual with autopsy-confirmed Alzheimer disease who underwent 18F-THK5351 and 11C-Pittsburgh compound B PET before death. Page 671

PET imaging of tau aggregates: Honer and colleagues detail preclinical in vitro and in vivo characterization of 3 novel 3H-labeled compounds that bind specifically to tau aggregates and have potential as future PET tracers. Page 675

Lower mGlu5 in alcohol dependence: Leurquin-Sterk and colleagues use dynamic 18F-FPEB imaging to investigate cerebral metabotropic glutamate receptor subtype 5 availability in alcohol-dependent individuals and controls. Page 682

Intragastric meal distribution: Orthey and colleagues evaluate visual assessments of fundic accommodation from solid-meal gastric-emptying scintigraphy and describe software developed to quantify the results of such scintigraphy. Page 691

FEATURED ARTICLE OF THE MONTHPET and NMDA GluN2B receptors: Krämer and colleagues describe development of 11C-Me-NB1 as a PET tracer for imaging GluN1- and GluN2B-containing N-methyl-d-aspartate receptors and investigate eliprodil dose-dependent receptor occupancy in rats. Page 698

177Lu-Lilotomab satetraxetan dosimetry: Blakkisrud and colleagues document biodistribution of a novel antibody–radionuclide conjugate as well as absorbed doses to organs at risk in patients with relapsed CD37-positive indolent non-Hodgkin lymphoma. Page 704